Art. -Nr.: HY-120599

Sabizabulin

Name: Sabizabulin
Brand: MedChemExpress
SKU: HY-120599
Price: 215.00 USD
Availability: InStock
Rating: 5 (4 reviews)

(Synonyms: VERU-111; ABI-231)

4 Cited Publications

Kundenbewertung

Based on 4 publication(s) in Google Scholar

VERU-111 (ABI-231) is a potent and orally active α and β tubulin inhibitor, which displays strong antiproliferative activity, with an average IC₅₀ of 5.2 nM against panels of melanoma and prostate cancer cell lines. VERU-111 (ABI-231) suppresses tumor growth and metastatic phenotypes of cervical cancer cells via targeting HPV E6 and E7, and has potential for the treatment of prostate cancer.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 99.00%
CAS. Nr.: 1332881-26-1
Formel: C₂₁H₁₉N₃O₄
Molecular Weight:377.39

Speicherung:

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Sabizabulin Chemical Structure

CAS. Nr.: 1332881-26-1

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (4)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll (6)
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

tubulin^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	10.4 nM Compound: ABI-231	Antiproliferative activity against human A375 cells measured after 72 hrs by MTS assay Antiproliferative activity against human A375 cells measured after 72 hrs by MTS assay	[PMID: 31860298]
A-375	IC₅₀	3.2 nM Compound: 6a	Antiproliferative activity against human A375 cells after 48 hrs by SRB assay Antiproliferative activity against human A375 cells after 48 hrs by SRB assay	[PMID: 22783954]
A-375	IC₅₀	8.1 nM Compound: ABI-231	Antiproliferative activity against human A375 cells after 72 hrs by MTT assay Antiproliferative activity against human A375 cells after 72 hrs by MTT assay	[PMID: 31251599]
A-375	IC₅₀	8.1 nM Compound: VERU-111	Cytotoxicity in human A375 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity in human A375 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 30122035]
DU-145	IC₅₀	3.9 nM Compound: 6a	Antiproliferative activity against human DU145 cells after 48 hrs by SRB assay Antiproliferative activity against human DU145 cells after 48 hrs by SRB assay	[PMID: 22783954]
LNCaP	IC₅₀	2.8 nM Compound: 6a	Antiproliferative activity against human LNCAP cells after 48 hrs by SRB assay Antiproliferative activity against human LNCAP cells after 48 hrs by SRB assay	[PMID: 22783954]
M14	IC₅₀	5.6 nM Compound: ABI-231	Antiproliferative activity against human M14 cells after 72 hrs by MTT assay Antiproliferative activity against human M14 cells after 72 hrs by MTT assay	[PMID: 31251599]
M14	IC₅₀	5.6 nM Compound: VERU-111	Cytotoxicity in human M14 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity in human M14 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 30122035]
M14	IC₅₀	8.9 nM Compound: ABI-231	Antiproliferative activity against human M14 cells measured after 72 hrs by MTS assay Antiproliferative activity against human M14 cells measured after 72 hrs by MTS assay	[PMID: 31860298]
MDA-MB-231	IC₅₀	8.2 nM Compound: ABI-231	Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by MTS assay Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by MTS assay	[PMID: 31860298]
MDA-MB-453	IC₅₀	13.6 nM Compound: ABI-231	Antiproliferative activity against human MDA-MB-453 cells measured after 72 hrs by MTS assay Antiproliferative activity against human MDA-MB-453 cells measured after 72 hrs by MTS assay	[PMID: 31860298]
PC-3	IC₅₀	3.7 nM Compound: 6a	Antiproliferative activity against human PC3 cells after 48 hrs by SRB assay Antiproliferative activity against human PC3 cells after 48 hrs by SRB assay	[PMID: 22783954]
RPMI-7951	IC₅₀	7.2 nM Compound: VERU-111	Cytotoxicity in human RPMI7951 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity in human RPMI7951 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 30122035]
RPMI-7951	IC₅₀	8.8 nM Compound: ABI-231	Antiproliferative activity against human RPMI7951 cells measured after 72 hrs by MTS assay Antiproliferative activity against human RPMI7951 cells measured after 72 hrs by MTS assay	[PMID: 31860298]
SK-BR-3	IC₅₀	13.3 nM Compound: ABI-231	Antiproliferative activity against human SK-BR-3 cells measured after 72 hrs by MTS assay Antiproliferative activity against human SK-BR-3 cells measured after 72 hrs by MTS assay	[PMID: 31860298]
WM164	IC₅₀	5.3 nM Compound: 6a	Antiproliferative activity against human WM164 cells after 48 hrs by SRB assay Antiproliferative activity against human WM164 cells after 48 hrs by SRB assay	[PMID: 22783954]
WM164	IC₅₀	7.2 nM Compound: ABI-231	Antiproliferative activity against human WM164 cells after 72 hrs by MTT assay Antiproliferative activity against human WM164 cells after 72 hrs by MTT assay	[PMID: 31251599]

In Vitro

VERU-111 (2.5-80 nM; 24-48 hours) inhibits Panc-1, AsPC-1 and HPAF-II cells growth in a dose and time-dependent manner (24 hours: IC₅₀s of 25, 35 and 35 nM, respectively; 48 hours: IC₅₀s of 11.8, 15.5, and 25 nM, respectively)^[4].
VERU-111 (5-20 nM; 24 hours) arrests Panc-1 and AsPC-1 cells in G2/M phase in a dose-dependent manner^[4].
VERU-111 (5-20 nM; 24 hours) shows dose-dependent inhibition of pro-Caspase 3 and 9 and activation of Caspase-3 and 9, induces the expression of Bax and Bad, and inhibits the expression of Bcl-2 and Bcl-xl proteins in both AsPC-1 and Panc-1 cells^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.

Cell Proliferation Assay^[4]

View Protocol

Cell Line:

Panc-1, AsPC-1, HPAF-II cells
Concentration:

2.5, 5, 10, 20, 40, 80 nM
Incubation Time:

24, 48 hours
Result:

Inhibited the growth of PanCa cells in a dose and time-dependent manner. The IC₅₀ of VERU-111 was 25, 35 and 35 nM in Panc-1, AsPC-1 and HPAF-II, respectively after 24 h treatment, while 48 h post-treatment it was 11.8, 15.5, and 25 nM.

Apoptosis Analysis^[4]

View Protocol

Cell Line:

Panc-1, AsPC-1 cells
Concentration:

5, 10, 20 nM
Incubation Time:

24 hours
Result:

Arrested Panc-1 and AsPC-1 cells in G2/M phase in a dose-dependent manner.

Western Blot Analysis^[4]

View Protocol

Cell Line:

AsPC-1 and Panc-1 cells
Concentration:

5, 10, 20 nM
Incubation Time:

24 hours
Result:

Dose-dependent inhibition of pro-Caspase 3 and 9 and activation of Caspase-3 and 9 in both AsPC-1 and Panc-1 cells. Induces the expression of Bax and Bad and inhibited the expression of Bcl-2 and Bcl-xl proteins.

In Vivo

VERU-111 (50 μg/mouse; intra-tumorally; 3 times per week for 3 weeks) effectively inhibits tumor growth as compared to vehicle-treated group. None of the mouse showed any apparent toxicity as constant increase of body weight in VERU-111 treated mice^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Six-week-old female athymic nude mice (bearing AsPC-1 cells)
Dosage:

50 μg/mouse
Administration:

Intra-tumorally; 3 times per week for 3 weeks
Result:

Effectively inhibited tumor growth.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 1332881-26-1
Appearance Solid
Molecular Weight 377.39
Formel C₂₁H₁₉N₃O₄
Color Light yellow to yellow
SMILES

O=C(C1=CNC(C2=CNC3=C2C=CC=C3)=N1)C4=CC(OC)=C(OC)C(OC)=C4
Synonyms

VERU-111; ABI-231
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Publications (4)

All

Sort by:

Journal Impact Factor

Mol Cancer Ther

RGN6024 is a brain-penetrant, small molecule tubulin destabilizer for the treatment of glioblastoma. [Abstract]

2025 Aug 1;24(8):1129-1144. PMID: 40397474
Biomedicines

Novel Brain-Penetrant, Small-Molecule Tubulin Destabilizers for the Treatment of Glioblastoma. [Abstract]

2024 Feb 9;12(2):406. PMID: 38398008
ESMO Gastrointestinal Oncology

2025 Sep 15;10:100237.
bioRxiv

2023 Jun 30.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 20 mg/mL (53.00 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.6498 mL

13.2489 mL

26.4978 mL

5 mM

0.5300 mL

2.6498 mL

5.2996 mL

10 mM

0.2650 mL

1.3249 mL

2.6498 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2 mg/mL (5.30 mM); Clear solution

This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2 mg/mL (5.30 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

All Cell Biology Animals and Diseases

Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
Patient-Derived Orthotopic Xenograft (PDOX)
Patient-derived orthotopic xenograft (PDOX) modeling implants fresh patient tumor tissue or patient-derived tumor cells into the anatomically corresponding organ or tissue site of immunodeficient mice, usually by surgical orthotopic implantation, to preserve patient tumor histology, local microenvironmental context, invasion, metastatic behavior, and treatment-response features better than subcutaneous implantation. PDOX readouts include tumor engraftment, orthotopic tumor growth, local invasion, metastasis, recurrence after resection, histologic similarity to the donor tumor, biomarker retention, molecular concordance, survival, and response or resistance to therapy. PDOX models are used for preclinical drug testing and individualized therapy evaluation, but engraftment success varies by tumor type and specimen quality.
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (284 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Wang Q, et al. Structure-Guided Design, Synthesis, and Biological Evaluation of (2-(1H-Indol-3-yl)-1H-imidazol-4-yl)(3,4,5-trimethoxyphenyl) Methanone (ABI-231) Analogues Targeting the Colchicine Binding Site in Tubulin. J Med Chem. 2019 Jul 12. [Content Brief]

[2]. Qinghui Wang, et al. Discovery of ABI-231 analogs targeting the colchicine site in tubulin for advanced melanoma. Cancer Research 76(14 Supplement):4848-4848.

[3]. Vivek Kashyap, et al. ABI-231: A novel small molecule suppresses tumor growth and metastatic phenotypes of cervical cancer cells via targeting Human papilloma virus (HPV) E6 and E7. Cancer Research 78(13 Supplement):679-679.

[4]. Kashyap VK, et al. Therapeutic efficacy of a novel βIII/βIV-tubulin inhibitor (VERU-111) in pancreatic cancer. J Exp Clin Cancer Res. 2019 Jan 23;38(1):29. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.6498 mL	13.2489 mL	26.4978 mL	66.2445 mL
	5 mM	0.5300 mL	2.6498 mL	5.2996 mL	13.2489 mL
	10 mM	0.2650 mL	1.3249 mL	2.6498 mL	6.6244 mL
	15 mM	0.1767 mL	0.8833 mL	1.7665 mL	4.4163 mL
	20 mM	0.1325 mL	0.6624 mL	1.3249 mL	3.3122 mL
	25 mM	0.1060 mL	0.5300 mL	1.0599 mL	2.6498 mL
	30 mM	0.0883 mL	0.4416 mL	0.8833 mL	2.2081 mL
	40 mM	0.0662 mL	0.3312 mL	0.6624 mL	1.6561 mL
	50 mM	0.0530 mL	0.2650 mL	0.5300 mL	1.3249 mL

Bioz

Keywords

Sabizabulin

4 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Sabizabulin

Publications Citing Use of MedChemExpress (MCE) Sabizabulin